Therma Bright Inc.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Recent News

  • Therma Bright Submits Application to Research Ethics Board for Approval of Clinical Trials for AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

    Toronto, Ontario--(Newsfile Corp. - March 11, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has submitted an application to an independent Research Ethics Board ("REB") for approval to conduct a clinical study with the Company's AcuVid TM rapid antigen test for detecting SARS CoV-2 virus in saliva. Approval is expected within a week, at which point Therma will submit a complete package, including the...

    2021-03-11 7:00 AM EST
  • Therma Bright Enters into Clinical Trial Agreement for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

    Toronto, Ontario--(Newsfile Corp. - February 26, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has entered into an agreement with a COVID-19 testing site located in the Greater Toronto Area to conduct a clinical study with the Company's AcuVid TM rapid antigen test for detecting SARS-CoV-2 virus in saliva. The testing site is located within the Greater Toronto Area that has one of the highest...

    2021-02-26 9:13 AM EST
  • Therma Bright Adds $1,171,875 to Treasury Through Exercise of Warrants and Options

    Toronto, Ontario--(Newsfile Corp. - January 29, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that in the past month, investors have exercised a total of 7,582,500 warrants and options to add $1,171,875 to the Company's treasury. With the addition of the $300,000, as previously reported in the press release on December 24th, 2020, the Company has added a total of $1,471,875 to the Company's treasury...

    2021-01-29 8:42 AM EST
  • Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the Test

    Toronto, Ontario--(Newsfile Corp. - January 25, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company announces that it has taken 100% control of the research and development, regulatory, manufacturing and commercialization of its saliva-based rapid antigen test. As a result, Therma Bright will retain 100% of all future revenue and profits from the sale of the saliva-based rapid antigen test. Therma Bright previously announced on November 4, 2020, that...

    2021-01-25 6:30 AM EST
  • Therma Bright Reports Improved Accuracy For Its COVID-19 Rapid Saliva Antigen Test, CoviSafeTM, And Prepares For Prospective Studies

    Toronto, Ontario--(Newsfile Corp. - January 18, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that the most recent results achieved with nanoComposix using banked human saliva samples and utilizing a CoviSafe™ prototype device indicate a test sensitivity of 86% and a specificity of 100% for Therma's CoviSafe™ rapid antigen test for detecting SARS-CoV-2 virus in saliva. As previously reported on December 7, 2020 preliminary results achieved during...

    2021-01-18 4:00 PM EST
  • Therma Bright Adds Veteran Manufacturing Expert to Advisory Team to Advance its Saliva-Based Rapid Antigen Test CoviSafe(TM)

    Toronto, Ontario--(Newsfile Corp. - January 15, 2021) -  Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce the appointment of Ian Levine to the advisory board to assist with future scaling for the manufacture of CoviSafe™.Mr. Levine will build the overall operations for the Therma Bright team to secure efficient and smooth delivery of CoviSafe™ to our global customers. Mr. Levine's experience in global manufacturing and distribution of regulated...

    2021-01-15 6:30 AM EST
  • Therma Bright Signs IR Agreement with Barwicki Investor Relations, Adds $300,000 to Treasury Through Exercise of Warrants and Options; and Grants Options

    Toronto, Ontario--(Newsfile Corp. - December 24, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, announces that it has engaged Barwicki Investor Relations to provide investor relations services to the Company. Founded by Andrew Barwicki in 2006, Barwicki Investor Relations is a full service investor relations firm representing publicly traded companies and pre-IPO companies. Andrew Barwicki has 25+ years experience in finance, investor relations, investment banking and marketing. Mr....

    2020-12-24 6:39 AM EST
  • Therma Bright Achieves High Accuracy Results from Feasibility Studies for Its COVID-19 Rapid Saliva Test, CoviSafe(TM)

    Toronto, Ontario--(Newsfile Corp. - December 7, 2020) -  Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce the preliminary results achieved during the feasibility studies indicate a test sensitivity of 80% and a specificity of over 90% for Therma's CoviSafe™ rapid test for detecting SARS-CoV-2 in saliva. Therma entered into an agreement with nanoComposix, a developer and manufacturer of rapid diagnostic tests to perform feasibility studies with a short...

    2020-12-07 5:07 PM EST